Rabies glycoprotein virus-like particles (vlps)
AssigneeNovavax, Inc.
InventorsGale Smith, Ye Liu
Life of this patent
Estimating the term…
Abstract
The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.
Claims21
1-33. (canceled)
A micellar particle comprising rabies virus (RV) glycoproteins (G proteins), wherein the G proteins form a trimer.
A method of treating or preventing a rabies infection comprising administering to a host a micellar particle comprising rabies virus (RV) glycoproteins (G proteins), wherein the G proteins form a trimer.
A method of making a micellar particle comprising rabies virus (RV) glycoproteins (G proteins), wherein the G proteins form a trimer comprising:
- (a) transforming a host cell to express an isolated nucleic acid encoding a RV G protein;
- and
- (b) culturing said host cell under conditions conducive to the production of said micellar VLP.
Dependencies are inferred from the claim text.